Pharma patent review releases discussion paper
27 November, 2012 by AusBiotechThe Federal Government panel reviewing patenting of pharmaceuticals in Australia has released a new paper for discussion.
Genzyme gets Australian approval for MS therapy Aubagio
27 November, 2012 by Tim DeanThe Therapeutic Goods Administration has approved Genzyme’s once-a-day MS treatment, Aubagio, for sale in Australia.
Newly discovered stem cell offers therapeutic potential
26 November, 2012 by Tim DeanA new type of stem cell could be developed into therapies for cardiovascular disease and other indications, and is being pursued by Australian biotech start-up Cynata.
Join study on careers in scientific research
22 November, 2012 by AusBiotechPeople working in scientific research are invited to participate in a survey examining careers in the biological sciences and chemistry related research workforce.
Bioniche picks US distributor for Immunocidin
22 November, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) has selected an exclusive US distributor for canine cancer product Immunocidin, which launched in the market last month.
Alchemia reaps $1.5m from anticoagulant in Q3
22 November, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) will receive $1.5m for the September quarter – its first proper share of the profits from sales of anticoagulant generic fondaparinux.
Sunshine Heart gets FDA tick for C-Pulse trial
21 November, 2012 by Dylan Bushell-EmblingSunshine Heart (ASX:SHC) is set to commence a North American trial of its C-Pulse Heart Assist System, after receiving regulatory approval from the FDA.
FDA clears AtCor blood pressure tool in US
21 November, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has received FDA approval to market SphygmoCor XCEL, its upgraded cardiovascular diagnostics tool, in the US.
Comment: Finding an alliance partner that will maximise the value of your assets
21 November, 2012 by Staff WritersMarcus Bain, Managing Director of Wescadia Group gives a checklist for biotechnology companies of what to look for in a potential industry partner.
Beat jetlag and sleep problems with new Australian invention
21 November, 2012 by Tim DeanA new invention from Flinders University scientists can help reset the body clock, beat jetlag and allows shift workers to remain more alert and get more sleep.
Sirtex up on news of planned $4.5m manufacturing plant in Germany
20 November, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) will invest $4.5m to build a manufacturing plant in Germany for its SIR-Spheres liver cancer treatments.
Mesoblast gets go-ahead from FDA to manufacture stem cells
20 November, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) and the US FDA have reached an agreement covering the company's manufacturing process for adult stem cells to be used in phase III trials.
Food standards body calls for comment on cost recovery
20 November, 2012 by AusBiotechFood Standards Australia New Zealand (FSANZ) invites comments on consultation papers it has released on proposed cost recovery arrangements for health claims applications.
Mesoblast reaffirms Teva partnership following share slump
19 November, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has reassured shareholders of the strength of its partnership with Teva Pharmaceutical Industries after rumours circulated that Teva may exit the stem cell collaboration.
LCT wins ethics nod for NZ Ntcell trial
16 November, 2012 by Dylan Bushell-EmblingLiving Cell Technologies (ASX:LCT) has secured ethics approval for the first in-human trial of its Ntcell treatment in patients with Parkinson's disease.
